At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 305 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING, PARALLEL GROUP STUDY TO EVALUATE SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF PF-05221304 ADMINISTERED DAILY FOR 16-WEEKS TO ADULT SUBJECTS WITH NONALCOHOLIC FATTY LIVER DISEASE
In Brief
A Phase 2 clinical trial evaluating Placebo and PF-05221304 for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Completed, enrolled 305 participants across 140 sites in 6 countries.
Detailed Summary
Phase 2a, dose-ranging Study with PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, Canada, Israel, Poland, Taiwan, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedAug 2017
Enrollment StartAug 2017
Primary CompletionFeb 2019
Study CompletionMar 2019
TodayJul 2026
First PostedAug 14, 2017
Enrollment StartAug 22, 2017
Primary CompletionFeb 26, 2019
Study CompletionMar 27, 2019
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 8.9 years ago
Interventions
Placebodrug
Placebo
PF-05221304drug
PF-05221304, Experimental Drug